[go: up one dir, main page]

MA49452A - Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire - Google Patents

Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire

Info

Publication number
MA49452A
MA49452A MA049452A MA49452A MA49452A MA 49452 A MA49452 A MA 49452A MA 049452 A MA049452 A MA 049452A MA 49452 A MA49452 A MA 49452A MA 49452 A MA49452 A MA 49452A
Authority
MA
Morocco
Prior art keywords
systemic
pulmonary artery
shunt thrombosis
preventing shunt
preventing
Prior art date
Application number
MA049452A
Other languages
English (en)
Inventor
Thomas G Diacovo
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA49452A publication Critical patent/MA49452A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA049452A 2017-06-23 2018-06-22 Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire MA49452A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762524102P 2017-06-23 2017-06-23

Publications (1)

Publication Number Publication Date
MA49452A true MA49452A (fr) 2021-05-05

Family

ID=62842064

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049452A MA49452A (fr) 2017-06-23 2018-06-22 Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire

Country Status (9)

Country Link
US (2) US11260071B2 (fr)
EP (1) EP3641784A1 (fr)
KR (1) KR102768341B1 (fr)
CN (1) CN110740736A (fr)
BR (1) BR112019022676A2 (fr)
CA (1) CA3060345A1 (fr)
MA (1) MA49452A (fr)
MX (1) MX2019015448A (fr)
WO (1) WO2018234565A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773040T3 (es) * 2009-11-11 2020-07-09 Chiesi Farm Spa Métodos de tratamiento o prevención de trombosis de stent
WO2025068477A1 (fr) * 2023-09-29 2025-04-03 Fundació Institut De Recerca De L´Hospital De La Santa Creu I Sant Pau Nouvelle génération d'antithrombotiques ciblant lrp5

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US759316A (en) 1902-12-06 1904-05-10 Walter C Runge Telephone-receiver.
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
ES2108425T3 (es) 1993-02-10 1997-12-16 Astra Pharma Prod Analogos de atp sustituidos con n-alquilo-2.
ID21635A (id) 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
HU227746B1 (en) 2000-07-06 2012-02-28 Ube Industries Hydropyridine derivative acid addition salts, process for their preparation, pharmaceutical compositions containing them and their use
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US20020123791A1 (en) 2000-12-28 2002-09-05 Harrison William J. Stent design with increased vessel coverage
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US7758630B2 (en) 2003-04-14 2010-07-20 Tryton Medical, Inc. Helical ostium support for treating vascular bifurcations
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
WO2005087266A1 (fr) 2004-03-05 2005-09-22 Vddi Pharmaceuticals Polytherapie bloquant l'agregation plaquettaire
US20080214599A1 (en) 2005-08-19 2008-09-04 John Thomas Brandt Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases
DE102006020386A1 (de) 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Verfahren zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen
US8252878B2 (en) 2006-07-14 2012-08-28 Biocompatibles Uk Limited Polymer
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
KR101473207B1 (ko) 2007-04-13 2014-12-16 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법
EP2152078B8 (fr) 2007-04-27 2021-03-17 CyDex Pharmaceuticals, Inc. Préparations contenant du clopidogrel et de la sulfoalkyl-éther cyclodextrine et méthodes d'utilisation
MX2009011843A (es) 2007-05-02 2010-04-22 Portola Pharm Inc Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible.
US20090043380A1 (en) 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Coatings for promoting endothelization of medical devices
US8998978B2 (en) 2007-09-28 2015-04-07 Abbott Cardiovascular Systems Inc. Stent formed from bioerodible metal-bioceramic composite
WO2009070624A1 (fr) 2007-11-27 2009-06-04 The Trustees Of The University Of Pennsylvania Endoprothèse vasculaire
CA2623449C (fr) 2008-03-27 2010-11-02 Lance Baldo Nouvelle application de la bivalirudine dans le traitement d'un syndrome coronarien aigu
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US8680052B1 (en) * 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (fr) * 2008-05-13 2009-11-19 The Medicines Company Conservation de l'inhibition de plaquettes durant une thérapie anti-plaquettes
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
KR101138294B1 (ko) 2008-09-24 2012-04-25 김형일 혈관벽 임시 골격용 생분해성 블랜드
US20120184504A1 (en) 2009-10-02 2012-07-19 Strony John T "The Use of a PAR-1 Antagonist in Combination with a P2Y12 ADP Receptor Antagonist for Inhibition of Thrombosis"
ES2773040T3 (es) 2009-11-11 2020-07-09 Chiesi Farm Spa Métodos de tratamiento o prevención de trombosis de stent
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2011134478A2 (fr) 2010-04-29 2011-11-03 Thrombologic Aps Méthodes de traitement de patients présentant un risque accru de développer des événements ischémiques et composés associés
BR112013020377B1 (pt) * 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
CN103860459A (zh) 2012-12-11 2014-06-18 天津市汉康医药生物技术有限公司 一种坎格雷洛注射剂及其制备方法
EA034550B1 (ru) * 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий
EP3189838A4 (fr) 2014-09-02 2018-04-18 Daiichi Sankyo Company, Limited Composition pharmaceutique pour inhiber la formation de thrombus et d'embolies après le placement de stent
MX391152B (es) 2015-01-14 2025-03-21 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.

Also Published As

Publication number Publication date
US20200054662A1 (en) 2020-02-20
WO2018234565A1 (fr) 2018-12-27
KR20200018481A (ko) 2020-02-19
KR102768341B1 (ko) 2025-02-18
CN110740736A (zh) 2020-01-31
US11260071B2 (en) 2022-03-01
US20240342205A1 (en) 2024-10-17
BR112019022676A2 (pt) 2020-05-19
RU2019142647A (ru) 2021-07-23
US20220117994A1 (en) 2022-04-21
CA3060345A1 (fr) 2018-12-27
RU2019142647A3 (fr) 2021-11-29
EP3641784A1 (fr) 2020-04-29
MX2019015448A (es) 2020-02-19

Similar Documents

Publication Publication Date Title
IL285151A (en) Methods of treating fgf21-associated disorders
MA52665A (fr) Procédé d'amélioration de l'expression de l'hémoglobine foetale
HUE063284T2 (hu) Eljárás vaszkuláris gyulladás megállapítására
EP3733242C0 (fr) L'assurance qualité de radiothérapie
IL262487B (en) Compounds and methods for treating neurological and cardiovascular conditions
EP3294865A4 (fr) Procédés de production d'épimérases et d'alcaloïdes benzylisoquinoléine
EP3604513A4 (fr) Composition pour la production de tagatose et procédé de production de tagatose l'utilisant
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
IL260730B (en) Process for preparing terpinene-4-ol
MA50169A (fr) Procédé de production d'un électrocatalyseur
LT3652491T (lt) Produkto liofilizavimo būdas
EP3476800A4 (fr) Sel métallique de bis(fluorosulfonyl)imide et sa méthode de préparation
EP3568077A4 (fr) Procédé d'estimation de volume sanguin
EP3398957A4 (fr) Procédé de synthèse de l'ételcalcétide
EP3592224A4 (fr) Méthode permettant de surveiller le traitement de maladies neuropsychiatriques
SG11202010677XA (en) Methods for the production of methacrylates
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
IL284374A (en) Methods of producing ustekinumab
IT201700093172A1 (it) Metodo per l'identificazione precoce di riacutizzazioni di broncopneumopatia cronica ostruttiva
EP3348278A4 (fr) Inhibiteur de la sécrétion d'exosomes
EP3612133A4 (fr) Échafaudages implantables pour le traitement de la sinusite
DE112018004164A5 (de) Verfahren zur Wertbestimmung von Parametern
EP3549711A4 (fr) Procédé de réglage d'âme
EP3441761A4 (fr) Procédé d'immunocoloration fluorescente
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1